LDL-cholestrol has been the recognised target in Lipid lowering therapy to prevent further cardiovascular events in high risk patients. Recently other targets like Non-HDL cholestrol , Apo-B lipoprotein have been considered targets in patients already on statin therapy.
Non-HDL cholesterol is already being used as a secondary target in the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-III) guidelines in patients with elevated triglyceride levels.
A post hoc analysis published in Circulation recently performed that combined data from 2 prospective, randomized clinical trials in which 10 001 ("Treating to New Targets")(TNT) and 8888 ("Incremental Decrease in End Points through Aggressive Lipid Lowering")(IDEAL) patients with established coronary heart disease were assigned to usual-dose or high-dose statin treatment. Read more..
Read the abstract of this study here...
Further discussion on this study and what it means to us in clinical practice is discussed here..
Sphere: Related Content
0 comments:
Post a Comment